gastrointestinal cancers were randomised to receive 16 g of glutamine per day for 8 days. or placebo. in a randomised double-blind trial before crossing over to the alternative supplement during the second treatment cycle. The supplement was well tolerated with no apparent adverse effects. but failed to have any significant effect on oral mucositis assessed by the patients or investigator. The possible reasons for this apparent lack of benefit are discussed.
Mucositis is a common and sometimes dose-limiting effect of chemotherapy. In patients receiving 5-FU and folinic acid it has been estimated that as many as 80% may develop mucositis, with 26% experiencing severe mucositis (Poon et al.. 1989) . It is both physically and psychologically distressing to the patient and not uncommonly leads to a reduction in dose intensity. Supportive care measures to diminish the incidence or severity of mucositis would have obvious clinical benefits. Allopurinol (Clark & Slevin. 1985) and cryotherapy (Mahood et al.. 1991) have both been suggested, but neither has demonstrated sufficient efficacy to become part of standard clinical practice. Recent work in animals suggests that the administration of glutamine may be a more promising solution.
Glutamine is the most abundant amino acid in the blood and in the free amino acid pool of the body (Bergstrom et al.. 1974) and its flux between tissues is greater than any other amino acid (Elia, 1991) . It is becoming increasingly apparent that glutamine plays a pivotal role in intermediary metabolism (Smith. 1990) . It is an important fuel for the mucosal cells of the gut (Windmueller & Spaeth. 1985) and a variety of other rapidly dividing cells, such as lymphocytes and macrophages (Newsholme et al., 1988) . In addition, it is a precursor for nucleic acid synthesis (Krebs, 1980) .
In several animal studies glutamine administration has been shown to lead to a reduction in the morbidity and mortality of animals treated with cytotoxic agents. Benefits have been observed with both parenteral and enteral administration of glutamine with a variety of chemotherapeutic agents including methotrexate (Fox et al.. 1988 ) and 5-FU (O'Dwsyer et al.. 1987) . In addition to the preservation of the morphological structure of the gut there was a significant reduction in the incidence of bacteraemia and improved survival (Fox et al.. 1988) .
Dose-response studies in healthy human volunteers have confirmed the safety of glutamine given both orally and intravenously (Ziegler et al.. 1990) , and in vitro studies suggest that it does not increase tumour growth (Klimberg et al.. 1990) . We have performed a pilot study to assess the feasibility of oral glutamine supplementation in patients with gastrointestinal cancers receiving 5-FU and foliic acid and to determine its effect on the incidence and severity of mucositis. particularly in the oral cavity. The patients recorded the number of sachets of supplement consumed each day and also completed a diary card beginning on the first day of supplementation and continuing daily for 28 days, which included an assessment of oral mucositis. number of bowel motions and stool consistency (Table I) . The number and nature of admissions to hospital between cycles of treatment was noted along with the response to therapy. An observer assessment of maximal mucositis was made at the end of each cycle according to the WHO classification. Differences between glutamine and placebo supplemented treatment cycles were assessed using Student's paired t-test.
Materials and methods

Twenty
The serum concentration of glutamine was investigated on day 5 of the first cycle in a subgroup of ten patients. The patients were asked to fast overnight and a pretreatment serum sample obtained the following morning (09.00 h) 5 min before administration of the 4g of glutamine or placebo supplement. A standard breakfast was given after 60 min. the chemotherapy after 150 min and lunch plus a second 4 g supplement of the same compound after 200 min. Thirteen There was no significant difference in haematological toxicity in nine patients who had full blood counts on day 15 of each cycle (Table III) . Patients were admitted to hospital between treatment cycles on only two occasions (one glutamine. one placebo).
The mean (s.d.) serum glutamine levels at time zero were 0.53 (0.06) gM for the patients receiving oral glutamine and 0.68 (0.20) ,4m for the placebo group. These means were not significantly different (P = 0.3). The time course of serum glutamine for the ten patients is shown in Figure 2 . Patient 1 showed a 2-fold rise in glutamine concentration after the initial glutamine dose, which reached a peak value of 1.33 tM within 15 min and declined with a half-life of 17 min. Basal levels were achieved after 60 min. No such concomitant change in glutamine concentration was observed after lunch supplemented with glutamine. In the other four patients no definitive increase in serum concentration was detected after glutamine dosing. Minimal changes in serum glutamine levels were associated with the placebo dosing. inappropriate to continue with the study in its present format. Several hypotheses can be raised to account for this lack of effect which must be addressed in future studies. In the majority of previous human studies glutamine has been administered intravenously (e.g. Ziegler et al., 1990 ). although evidence from animal studies suggests that similar decreases in the incidence and severity of mucositis occur with enteral glutamine supplementation (Fox et al.. 1988) . To date most studies have considered the impact of glutamine on the large bowel, and this is the first study to have specifically addressed the issue of oral mucositis. In the normal state the mucosal cells of the gut receive glutamine both from the gut lumen and from the systemic circulation. In the oral cavity the latter is the predominant source. We hypothesised that by using the glutamine solution as a mouthwash free glutamine would be made available for uptake by the cells of the oral mucosa and reduce the severity or duration of mucositis. However, this did not occur. It is possible that either these stratified squamous cells do not exhibit the preference for glutamine as a fuel demonstrated by enterocytes and colonocytes or that the duration of exposure to glutamine was too short. Pharmacokinetic studies of glutamine administration to healthy subjects have shown a significant increase in plasma gutamine concentrations with oral doses of 0.1 g kg-'
body weight or greater (Ziegler et al.. 1990) . No such increases were measured in a subgroup of these patients when the supplement was given following an overnight fast or with a meal. Hence. no additional benefit to the oral mucosa would be anticipated from the supply of glutamine via the systemic circulation.
The dose of glutamine given in this study (4.13 g of nitrogen) must also be considered. This dose was similar to the dose used in animals (as a proportion of total nitrogen intake) and shown to have a beneficial effect on the intestinal mucosa. However. recent human studies which have shown positive benefits have given 0.57 g of glutamine per kg, more than twice the dose in this study (Ziegler et al., 1992; Schloerb & Amare. 1993) , and via the intravenous route.
Increasing the dose of glutamine via the oral route is not easy. The solubility of glutamine is only 3.6% at 23°C (Elia, 1992) . Hence, a dose of 16g requires over 400ml of fluid. This is a significant burden to patients, who are often anorexic and suffer from oral mucositis.
This study differed from many others, both animal and human, in the attention given to clinical end points. Studies in laboratory animals receiving cytotoxic agents who have received glutamine-enriched diets have generally focused on the effects on the gut in terms of the maintenance of mucosal structure, and have inferred that preservation of the gut structure will lead to improvements in clinical end points. In clinical studies nitrogen balance is commonly used as a marker of clinical benefit, yet a direct relationship between the two has yet to be shown. In the study of Ziegler et al. (1992) in which intravenous glutamine supplementation was given to patients receiving bone marrow transplants. there was an improvement in nitrogen balance at a dose of 0.57 g kg-', which was not observed at the lower dose rate of 0.285 g kg-', but the direct clinical relevance of this is unclear. There was also a significant reduction in sepsis. shown by a decrease in the number of positive cultures, but there was no reduction in oral mucositis. In our study improvements in gut structure and nitrogen balance cannot be ruled out, but with respect to the principal clinical end point in this study, that of oral mucositis, there was no apparent effect of glutamine supplementation. Clearly, further evaluation is required of the potential role of glutamine supplementation in the management of cytotoxic-induced mucositis in terms of the most appropriate dose of glutamine. route of supplementation and clinically relevant markers of benefit. A better understanding of the mechanism of glutamine action, which is currently unclear, can only assist the rational application of this nutritional pharmacology.
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